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In Brief
Natural product indole-3-carbinol (I3C),
commonly found in cruciferous
vegetables, has antiproliferative effects in
cancer cells. Rothman et al. show that for
one class of the synthetic derivatives of
I3C, N-BICs, the first step in their
mechanism of anticancer action is
conversion to reactive electrophiles
mediated by SULT1A1.
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http://dx.doi.org/10.1016/j.chembiol.2015.06.025SUMMARY
In an attempt to identify novel therapeutics and
mechanisms to differentially kill tumor cells using
phenotypic screening, we identified N-benzyl indole
carbinols (N-BICs), synthetic analogs of the natural
product indole-3-carbinol (I3C). To understand the
mode of action for the molecules we employed
Cancer Cell Line Encyclopedia viability profiling
and correlative informatics analysis to identify and
ultimately confirm the phase II metabolic enzyme
sulfotransferase 1A1 (SULT1A1) as the essential
factor for compound selectivity. Further studies
demonstrate that SULT1A1 activates the N-BICs
by rendering the compounds strong electrophiles
which can alkylate cellular proteins and thereby
induce cell death. This study demonstrates that
the selectivity profile for N-BICs is through conver-
sion by SULT1A1 from an inactive prodrug to an
active species that induces cell death and tumor
suppression.
INTRODUCTION
The N-benzyl indole carbinols (N-BICs) are synthetic analogs
of the natural product indole-3-carbinol (I3C) (Figure 1A),
commonly found in cruciferous vegetables and reported to
have antiproliferative properties in cancer cells (Aggarwal and
Ichikawa, 2005; Bradlow et al., 1999; Chinni et al., 2001; Safe
et al., 2008; Wang et al., 2013; Weng et al., 2008). I3C is an inac-
tive acid-sensitive molecule proposed to be activated upon
contact with gastric acids after consumption of Brassica vege-
tables. The stomach acid renders the molecule self-reactive,
forming di-indoyl-methane (DIM) as well as other products1228 Chemistry & Biology 22, 1228–1237, September 17, 2015 ª201(Grose and Bjeldanes, 1992). Notably, DIM is widely commer-
cially available as a natural therapy for the treatment of breast,
uterine, and colon cancer, among other indications (Biersack
and Schobert, 2012; Chen et al., 2013; Li et al., 2013; Sarkar
and Li, 2009; Vivar et al., 2010). It is speculated to act in the
estrogen pathway, although this claim is controversial. The
N-BICs (Figure 1A) differ from the parent I3C by virtue of having
a benzyl group off of the indole nitrogen, rendering them more
stable than the parent to acid (Aronchik et al., 2012; Nguyen
et al., 2010).
To date the N-BICs mechanism of action has remained un-
clear. Nguyen et al. (2010) identified an N-benzyl derivative of
I3C, which is a more potent analog of I3C in killing estrogen-
responsive (MCF-7) and estrogen-independent (MDA-MB-231)
human breast cancer cells. They further suggested that the
parent and analogs are elastase inhibitors that disrupt cyclin E
protein processing. Other studies have suggested that oncrasin,
an aldehyde analog of N-BICs, selectively kills mutant K-Ras cell
lines (Guo et al., 2008); its antitumor activity is reported to be
through activating JNK and inhibiting STAT3 (Guo et al., 2011;
Gupta et al., 2013).
Sulfotransferase 1A1 (SULT1A1) and other SULTs are phase II
metabolic enzymes, which append a sulfate group to an aro-
matic or aliphatic hydroxyl group on xenobiotic compounds.
This renders the compound more soluble for the purpose of
excretion, and often less toxic or non-toxic. However, the sulfo-
nated compound may also be rendered an electrophile, as the
sulfate is a good leaving group. Many common drugs are sub-
strates for SULTs; for example, acetaminophen, minoxidil, and
dopamine are all SULT substrates (James and Ambadapadi,
2013; Wang and James, 2006).
Here, we demonstrate that N-BICs selectively kill cancer cells,
expressing high levels of SULT1A1. Furthermore, we understand
that SULT1A1 activates the N-BICs by rendering the compounds
strong electrophiles which can alkylate multiple proteins in the
cell, and induce cell death and tumor suppression.5 Elsevier Ltd All rights reserved
Figure 1. Sensitivity of N-BICs in HCT116
p53 Isogenic Cells and in CCLE Profiling
(A) Chemical structures of compounds refer-
enced: the natural product indole-3-carbinol,
the skeleton structure of N-BICs, and the
synthetic analogs N-BIC 1, N-BIC 2, and
N-BIC 3.
(B) Cell viability assay in HCT116. Cells
were treated for 72 hr and cell viability was
measured with CellTiter-Glo Luminescent Cell
Viability Assay. Error bars represent the stan-
dard deviation from three replicates. WT, wild-
type. Mut, mutant.
(C) Colony formation assay in HCT116. WT, wild-
type. Mut, mutant.
(D and E) Differential selectivity of (D) N-BIC 2 and
(E) doxorubicin in CCLE profiling. Each point rep-
resents one cell line; x axis denotes the concen-
tration of compound at which the curve crosses
50% cell death (cross point); and y axis denotes
the maximum cell death when normalized to
DMSO (0%) and the broadly cytotoxic MG132
(100%).RESULTS
Identification of N-BICs
Identification of a drug that differentially targets tumors
harboring p53 genetic alterations would be of tremendous
value to the medical community. To identify such a molecule
we embarked on a chemical genetics approach using p53
isogenic cell lines. Engineered HCT116 cells harboring
different p53 status (wild-type [WT], mutant [R248W], or null)
(Sur et al., 2009) were treated with the Novartis Compound
Library using ultrahigh-throughput screening technologies
to identify those that could selectively kill the mutant or null
strains. Cell viability was used as the primary screening
assay, and promising hit molecules were subsequently tested
in a colony formation assay. From these efforts a promising
candidate series emerged, as exemplified by N-BIC 1
(Figure 1A).
The cytotoxic profile for the compound is shown in Fig-
ure 1B. In a reconfirmation dose-response format of the
primary cell viability assay across the three cell lines, N-BIC
1 most potently and effectively kills HCT116-p53 mutant
cells with an IC50 of 300 nM and a maximum effect of 60%Chemistry & Biology 22, 1228–1237, September 17, 2015inhibition of viability (100% viability is
DMSO treatment, 0% viability is no
cells). The compound is slightly less
potent and significantly less efficacious
on p53-WT cells and has no effect on
p53 null cells, suggesting a phenotype
associated specifically with the p53
mutant genotype. This trend was repli-
cated in colony formation assays (Fig-
ure 1C). We wanted to discover whether
this observation in isogenic lines would
hold in a larger set of non-engineered
cancer cell lines. To better understand
what drives the differential sensitivity,N-BIC 1 and several analogs were subjected to a larger
viability panel assessment.
Characterization of Cell Sensitivity to N-BICs
Several N-BICs were passed through a patient stratification plat-
form termed the cell line profiling platform (CLiP). This approach
sequentially tests compounds for viability effects in an eight-
point dose-response format across approximately 500 cell lines
derived from the Cancer Cell Line Encyclopedia (CCLE). The
CCLE comprises a compilation of well-characterized genetic
and expression-based features from human cancer cell lines.
When coupled with pharmacological profiles across the 500
cell lines used in CLiP, this collection allows identification of
genetic-, lineage-, and gene-expression-based predictors of
drug sensitivity (Barretina et al., 2012).
The compound N-BIC 2 (Figure 1A) was tested in this subset
of the CCLE and produced a selective profile (Figure 1D). Each
dose-response curve for a given cell line is represented as a sin-
gle spot on the graph where the x axis is a measure of potency
(crossing point) and the y axis is a measure of efficacy (maximal
inhibition compared with a broadly cytotoxic control). Cell lines
on the lower left of the plot are considered highly sensitive toª2015 Elsevier Ltd All rights reserved 1229
Figure 2. Correlation of N-BIC Cell Sensitivity with SULT1A1 Expression
(A) Global view of cell lines treated with N-BIC 2 in CLiP and SULT1A1 expression data from CCLE profiling. Each point represents one cell line. X axis denotes
cross point; y axis denotes SULT1A1 mRNA expression levels.
(B) Cell lines clustered by selected tissue types from global view.
(C) Liver cell lines from global view arranged according to SULT1A1 expression levels.
(D) Validation of selected liver line data from CCLE initiative. Error bars represent the standard deviation from three replicates. Top, SULT1A1 mRNA levels;
bottom, SULT1A1 protein levels.
(E) Effect of N-BIC 1 (left) and DNA damage reagent, cisplatin (right) on liver cells with various SULT1A1 levels. Error bars represent the standard deviation from
three replicates.compound and cell lines on the upper right are considered
insensitive. Each N-BIC had a relatively specific profile and
was able to kill a subset of cells (deemed N-BICs sensitive)
without affectingmost of the cell lines in the experiment (deemed
N-BICs insensitive). This is in contrast to standard-of-care com-
pounds, such as doxorubicin, which demonstrate general
toxicity across the cell lines (Figure 1E). Given the richness of in-
formation available on the CCLE lines, this differential cytotox-
icity can be a powerful tool to determine target(s) and/or poten-
tial mechanism(s) of action for a compound of unknown function.
SULT1A1 Identified as a Sensitivity Feature
An in-depth analytical comparison between sensitive and insen-
sitive cells was used to identify the characteristic features asso-
ciated with sensitivity. Sensitive cells were defined as those with
a crossing point of less than 2 mM, and insensitive cells were
defined as those with a crossing point greater than 6.5 mM.
The analysis identifies mutations, amplifications, mRNA levels,1230 Chemistry & Biology 22, 1228–1237, September 17, 2015 ª201or lineages as features that differ between the sensitive and
insensitive cell line populations. The data revealed that p53
mutational status was not a statistically distinguishing feature;
however, SULT1A1 expression was noted as a strikingly statisti-
cally significant feature (p value for N-BIC 1, 2.38 3 1019;
p value for N-BIC 2, 2.99 3 1023) which could distinguish the
two populations. Sensitivity was highly correlated with SULT1A1
mRNA levels; that is, cells with high SULT1A1mRNAwere effec-
tively killed by N-BICs and cells with low SULT1A1 mRNA were
resistant to N-BICs (Figure 2A). Furthermore, there is good cor-
relation of SULT1A1 expression and sensitivity across different
lineages, especially in breast, kidney, ovary, and liver cancer
cells (Figure 2B).
Liver cells provided a good lineage-matched set of lines to
further validate the correlation between compound sensitivity
and SULT1A1 expression; there are 16 liver-derived cancer
cell lines included in the CLiP set with a wide array of SULT1A1
expression. Figure 2C shows the clear correlation of SULT1A5 Elsevier Ltd All rights reserved
Figure 3. Genetic Validation of the Require-
ment of SULT1A1 for Cell Sensitivity to
N-BIC 1
(A) Knockdown of SULT1A1 in sensitive Caov-3
cells. Left: Cell viability; right: knockdown level.
Error bars represent the standard deviation from
three replicates. NTC, non-target control.
(B) Ectopic expression of SULT1A1 in insensitive
Saos-2 cells. Left: Viability; right: SULT1A1 protein
levels. Error bars represent the standard deviation
from three replicates.level with sensitivity in these cells. To further validate the profiling
data, we selected two cell lines each with low, medium, or high
SULT1A1 based on mRNA profiling data, to assess mRNA and
protein levels (Figure 2D). There is a good correlation between
protein levels and observed CLiP sensitivity for the cancer cell
lines. To confirm sensitivity among all of these liver lines, cell
viability upon compound treatment was measured. N-BIC 1
showed strong selectivity, potently inhibiting the growth of cells
with high SULT1A1 level. In contrast, cisplatin repressed all the
cell growth with similar potency (Figure 2E).
SULT1A1 Is Required for Cellular Sensitivity
To confirm the necessity of SULT1A1 for cell sensitivity to
N-BICs, Caov-3 cells were subjected to SULT1A1 knockdown
followed by compound treatment. Several short-hairpin RNAs
(shRNAs) were assessed for knockdown efficiency of SULT1A1;
each shRNA produced a different knockdown efficiency, as
observed in Caov-3 cells (Figure 3A). shRNA3 showed the most
effective knockdown and rendered the cell line insensitive to
compound treatment.Of note, the relative potencyof the shRNAs
for knockdown was directly correlated to modulating sensitivity
to compound: shRNA3wasmost effective and rendered the cells
insensitive, shRNA2 was non-functional and had minimal effect,
and shRNA1 had an intermediate knockdown with a partial
rescue of sensitivity. Similar results were observed in the engi-
neeredHCT116 p53mutant cells, thus strengthening the correla-
tion of SULT1A1 level with sensitivity to N-BICs (data not shown).
To determine the sufficiency of SULT1A1 for compound sensi-
tivity, we performed a reciprocal experiment, introducing the
gene into a cell line with undetectable SULT1A1 to determine
whether the gene will confer sensitivity. Stable cell lines were es-
tablished to overexpress SULT1A1 in H1299 and Saos-2 lines.Chemistry & Biology 22, 1228–1237, September 17, 2015Both lines natively have low SULT1A1
expression and are insensitive to
N-BICs. As shown in Figure 3B, Saos-2
cells overexpressing SULT1A1 become
sensitive to compound treatment. The
same result was observed in H1299 cells
(data not shown). This finding, along with
the knockdown data, demonstrates that
SULT1A1 is required for N-BICs efficacy
as a tumor cell-killing compound.
SULT1A1 Activates N-BICs
We hypothesized that cells with more
SULT1A1 are able to convert the N-BICsefficiently to an electrophile at neutral pH by sulfonylating the
free hydoxyl. The sulfate group is a better leaving group than
the hydroxyl and can rapidly form the alkylating agent, which is
then trapped by proteins in the cell (Figure 4A).
When synthesizing the compounds we noticed a susceptibility
to acidic conditions under which the compounds would rapidly
degrade, forming dimers or other multimers in solution. There
is a literature precedent for the reactivity of I3C under acidic con-
ditions, and this appears to translate to the benzylic analogs
(Nguyen et al., 2010). We found that the compounds were stable
in buffered aqueous environments. We next decided to probe
the ability of the compound to form any adducts with biologically
relevant nucleophiles. Combining compound with glutathione
under varying pH demonstrated the trend that pH was inversely
correlated with reactivity. That is, acidic conditions promoted
reactivity while basic conditions significantly hindered reactivity
(Figure S1). Of note, at physiological pH the reactivity is less
than 5% of that at pH 4.5.
We built a structure-activity relationship (SAR) to better under-
stand the correlation between compound reactivity and com-
pound efficacy as measured by the ability to kill HCT116 cells.
As noted in Figure 4B, compounds unable to form the elimination
product electrophile were inactive, while those that did have the
functionality to become an electrophile maintained the ability to
kill HCT116 cells.
We demonstrated that N-BICs are substrates for purified
SULT1A1 in vitro. Purified protein was combined with 30-phos-
phoadenosine-50-phosphosulfate (PAPS) and compound in the
presence of 4-nitrophenol to measure the relative substrate
reactivity with SULT1A1 (Frame et al., 2000). N-BICs were found
to be substrates of SULT1A1 via a method described in the liter-
ature (Figure 4C).ª2015 Elsevier Ltd All rights reserved 1231
Figure 4. Transient Electrophile Formation from N-BICs by SULT1A1
(A) SULT1A1 promotes the formation of a transient electrophilic species by generating a good leaving group under physiological pH. The electrophile can react
with biological nucleophiles such as the thiol from a cysteine. Natural SULT1A1 substrates, such as polyphenols, block N-BICs ability to covalently modify
proteins.
(B) SAR of N-BICs at hydroxyl group R. HCT116 p53mutant cell viability observed with 1 mM compound treatment. Error bars represent the standard deviation
from three replicates.
(C) SULT1A1 sulfonylates N-BIC 1 in the presence of p-nitrophenylsulfate and 50-phosphoadenosine-30-phosphosulfate. Error bars represent the standard
deviation from two replicates.SULT1A1 Triggers N-BICs to Covalently Modify Cellular
Proteins
To rule out a common artifact of differential permeability and/
or active efflux pumping, we looked at the relative intracellular
concentrations of compound in the HCT116-isogenic cells.
As seen in Figure 5A, compound resides in all three isogenic
lines under steady-state conditions. In fact, it appears that
HCT116-p53 null cells (compound resistant) have most free
compound, and we speculate that this is because compound
is unreactive in this cell line due to low SULT1A1 levels. We
evaluated the levels of SULT1A1 in the isogenic lines and
found that protein levels correlated well with sensitivity (Fig-
ure 5A), supporting the notion that SULT1A1 effectively re-
duces the free pool of parental compound by conversion to
an active form.
Next, we wanted to see whether the mechanism of action of
the compound was due to targeting of a single protein or a
more general, non-specific labeling. While exploring compound
SAR, we found that larger changes in the region of the benzyl
group were well tolerated. A naphthyl analog with a biotin tag ap-
pended to it (N-BIC 3, Figure 1A) demonstrated good potency
against HCT116 cells, with the same selectivity observed for
N-BIC 1 (Figure S2). This gave us a tool compound to further
probe the reactivity of the compound in living cells. To identify
the protein(s) covalently labeled with N-BIC 3, treated cells
were lysed and total protein was run on SDS-PAGE and probed
for the biotin tag. The compound labeled a discrete set of
proteins. This labeling could be competed with a non-labeled1232 Chemistry & Biology 22, 1228–1237, September 17, 2015 ª201compound, N-BIC 1 (Figure 5B). We next looked at subcellular
localization. Cells were treated with N-BIC 3, fixed, washed,
and probed for the biotin tag. As seen in Figure 5C, compound
covalently modifies protein(s) throughout the cells and appears
diffuse as readout by biotin tag staining. Staining intensity
correlated with N-BIC reactivity. In addition, N-BIC 3 can
be competed by pretreatment with non-labeled compound
(N-BIC 1), thus preventing covalent modification with the
biotin-tagged molecule.
Based on a publication studying the effects on reactive
oxygen species by N-BICs type compounds (Wei et al., 2010),
we decided to recapitulate the results in our cells for orthogonal
confirmation. Our results are in line with what (Wei et al., 2010)
observed: particularly intriguing is the fact that polyphenolic an-
tioxidants such as nordihydroguaiaretic acid (NDGA) were able
to render cells insensitive to compound treatment, while other
structural classes of antioxidants had no effect on compound
efficacy, e.g., N-acetylcysteine (NAC) (Figure 5D). In addition,
N-BIC 1 reduced Nrf2 protein levels in HCT116-p53 mutant
and WT cells but not in p53 null cells, which correlated well
with their sensitivities to N-BICs (Figure S3).
We then hypothesized that the polyphenolic antioxidants were
able to act as competitive substrates with N-BICs for SULT1A1
(Figure 4). The polyphenolic antioxidants are natural substrates
for SULT1A1 (Wang and James, 2006) and can compete with
N-BICs, thus preventing the ability of N-BICs to label proteins
and kill cells. We found that treatment of cells with polyphenolic
antioxidants precluded covalent modification of protein by5 Elsevier Ltd All rights reserved
Figure 5. N-BICs Covalently Modify Cellular
Proteins
(A) Top: Free compound detected inside HCT116-
p53 isogenic lines by mass spectrometry. Bottom:
Corresponding SULT1A1 protein levels. Error
bars represent the standard deviation from three
replicates. WT, wild-type; Mut, mutant.
(B and C) Detection of covalently modified proteins
in HCT116 p53mutant cells treatedwith N-BIC 3 by
(B) western blot and (C) immunostaining (overall
intensity is shown on the left and the magnification
of cells is shown on the right). WT, wild-type; Mut,
mutant.
(D and E) Effects of various antioxidants on N-BIC 3
induced (D) cell death and (E) covalent protein
modification in HCT116 p53 mutant cells. Error
bars represent the standard deviation from three
replicates.N-BIC 3 (Figure 5E). Polyphenolic compounds such as quercetin
are known potent substrates of purified SULT1A1 (Wang and
James, 2006).
N-BICs Do Not Accumulate In Vivo
As covalent modification can be a liability when designing a drug,
we wanted to examine the in vivo metabolism of the compound.
To assess any accumulation concerns, we ran a mass balance
experiment with radiolabeled compound. N-BIC 1 was labeled
at the indole-2 position with 14C. Tumor-bearingmice were given
a single dose of compound andmonitored for 6 days, after whichChemistry & Biology 22, 1228–1237, September 17, 2015they were euthanized and all samples
collected. We found that 99% of the com-
pound was recovered with 1% of the ma-
terial remaining in the animal (Table S1).
Metabolic identification studies helped
explain this efficient clearance of a com-
pound with the potential for covalent
modification in the animal. As seen in Fig-
ure 6A, the majority of the compound
is oxidized at the methyl alcohol: first to
the corresponding aldehyde, then to the
acid. The acid can then be glucuronidated
to aid in excretion. Of note, oxidation
of the methyl alcohol blocks the com-
pound’s ability to become an electrophile,
rendering that part of themolecule inert as
shown in Figure 4.
N-BICs Selectively Repress Tumor
Growth
Interested in the selectivity of this com-
pound class, we examined the in vivo effi-
cacyofN-BIC1 in tumor-bearingmice. In a
preliminary pharmacokinetic and pharma-
codynamic (PD) study in nude mice, we
observed good exposure of the parent
molecule in the tumor for up to 24 hr after
a single dose. In addition, p21 induction
was robust at earlier time points as a PDmarker (Figure 6B). In the efficacy experiment, we found that
N-BIC 1 could significantly slow the growth of HCT116-p53
mutant tumor xenografts (treatment/control ratio [T/C] = 0.59)
(Figure 6C); as well as HT-29 (T/C = 0.40) and Caov-3 (T/C =
0.35) xenograft models (Figure S4). Furthermore, we tested that
this effect was specific to cell lines sensitive to N-BIC 1 in vitro.
As seen inFigure 6D,p53-null tumor xenograftswere not affected
by compound treatment and grew comparably with vehicle con-
trol tumors. A secondarmof the studycompared this directlywith
p53-mutant and N-BICs sensitive cells; their growth was signifi-
cantly slowed by compound treatment (T/C = 0.5).ª2015 Elsevier Ltd All rights reserved 1233
Figure 6. Effect of N-BIC 1 on Tumor Growth
In Vivo
(A) Metabolite identification of N-BIC 1. Metabo-
lites generated from cells treated with radiolabeled
N-BIC 1 analyzed by LC-MS.
(B) Pharmacokinetic and pharmacodynamic
readout in tumor-bearing mice. Single dose given
intravenously (30 mg/kg body weight).
(C) Efficacy on tumor growth with three different
dosing schemes. (p < 0.0009, T/C = 0.59) (HCT116
p53 mutant). T/C, treatment/control.
(D) Efficacy on growth in tumors with different
SULT1A1 levels. HCT116 p53 mutant (high
SULT1A1, ***p < 0.0001, T/C = 0.5) and HCT116
p53 null (lowSULT1A1). SULT1A1 levels are shown
in Figure 5A. Error bars represent the standard
deviation from eight mice. T/C, treatment/control.DISCUSSION
In an effort to identify compounds and targets that selectively
target p53-mutant and/or null cell over WT, we identified the
N-BICs, which selectively kill R248W engineered p53-mutant
HCT116 cells preferably over p53-WT cells and have no effect
on p53-null cells. N-BICs are synthetic analogs of the natural
product I3C found in cruciferous vegetables, which has been
shown in the literature to demonstrate antiproliferative effects
on cancer cells with no known mechanism.
We identified a strong correlation between cell sensitivity to
N-BICs and SULT1A1 expression levels in a broad set of cell
lines from the CCLE collection, and confirmed that SULT1A1 is
the required element to confer cellular sensitivity to N-BICs.
SULT1A1 knockdown in p53-mutant cells results in loss of sensi-
tivity to compound while overexpression of SULT1A1 renders
insensitive p53-null cells sensitive to compound. The killing ef-
fect of N-BICs requires SULT1A1 expression, but to what extent
this is correlated with p53 pathway status is unknown. It will be
interesting to determine whether p53 affects SULT1A1 expres-
sion either directly or indirectly. We found that p53 null cells1234 Chemistry & Biology 22, 1228–1237, September 17, 2015 ª2015 Elsevier Ltd All rightsnatively have low SULT1A1 protein levels.
However, we found no correlation be-
tween p53 mutant or WT status with
SULT1A1 expression levels (data not
shown).
SULT1A1 is a member of the sulfo-
transferase family of phase II metabolic
enzymes. Sulfotransferases increase
compound solubility by transferring the
sulfate group to their substrates, and
N-BICs are one kind of substrate for
SULT1A1. SULT1A1 converts the com-
pound to an electrophile, which cova-
lently modifies a range of proteins, ulti-
mately leading to cell death. Variable
SULT1A1 levels among cell types, tis-
sues, and target local environments or
structures (such as pH and accessibility)
may confer specificity and selectivity to
covalent modifiers including the N-BICs.Whether N-BICs can achieve a suitable therapeutic index to
allow clinical application remains to be seen. Similar mecha-
nisms are currently under investigation: aminoflavone (NSC
686288) is a compound known to be processed initially by cyto-
chrome P450 and subsequently by SULT1A1 and SULT1A2
(Meng et al., 2006). Its metabolites covalently modify cellular
proteins and DNA, which leads to cell death. There is a good
correlation between SULT1A1 expression and aminoflavone
sensitivity. Clinical trials for aminoflavone are ongoing, although
the outcome is unclear at present.
Small molecules have been reported in the literature to reacti-
vate mutant p53 via a covalent modification mechanism. MIRA
and PRIMA are two key examples functioning via mechanisms
different from those of N-BICs. MIRA is an inherent electrophile
containing a maleimide moiety, which decreases compound
selectivity in protein binding and cell killing. PRIMA requires acti-
vation to an electrophile via a time- and temperature-dependent
chemical mechanism. Again, this decreases the selectivity
among which cells are killed by compound treatment. N-BICs
have a more discrete triggering mechanism requiring enzymatic
expression of SULT1A1. Cells with little or no SULT1A1 cannotreserved
convert N-BICs to the electrophile, and thus are not affected by
compound treatment. In addition, we observed that PRIMA is not
a substrate of SULT1A1 and MIRA is an inhibitor of the protein
(data not shown), where N-BICs are substrates. It is possible
that N-BICs, MIRA, and PRIMA induce cell death via similar
mechanisms downstream of covalent modification; however,
N-BICs afford cell line selectivity based on SULT1A1 expression
levels. Furthermore, we found that N-BICs reduce Nrf2 in sensi-
tive cells but not in insensitive cells, which indicates that
depriving the cells of Nrf2 may contribute to the loss of cell
viability.
There is reasonable concern for compound accumulation
when introducing a compound with a covalent mechanism of ac-
tion into animals. The combination of the N-BICs trigger mecha-
nism and in vivo metabolism renders them relatively safe and
efficiently cleared from themajority of themouse body. Accumu-
lation in animals due to covalent modification was not found
via radiolabeled mass balance experiments. Oxidation of the
N-BICs by phase I enzymes renders the compound unable to
convert to the electrophile by SULT1A1 activation, and makes
it more amenable to excretion by modification to the glucuroni-
date. At the same time, enough compound could reach the im-
planted tumor to elicit an effect. This allays any concerns and
demonstrates the specificity triggered by the enzyme location.
Furthermore, we demonstrated that tumor growth was signifi-
cantly repressed by N-BICs treatment. In combination, the
N-BICs show promise as a selective cancer therapeutic based
on SULT1A1 levels.
We observed a trend that p53-mutant cells have relatively
high SULT1A1 levels. One future direction would be to investi-
gate the correlation between p53 status and SULT1A1
levels. This selectivity mechanism via SULT1A1 activation of
compound could lead to therapeutics for tumors that are p53-
mutant, which represents an unmet medical need. In conclu-
sion, the N-BICs show promise as a selective cancer therapeu-
tic based on SULT1A1.SIGNIFICANCE
The mechanism for I3C’s antiproliferation in cancer cells re-
mains uncertain. Understanding this mechanism of action
would be of great value to cancer treatment. Our computa-
tional analysis of cell line profiling of about 500 cell lines
identified for the first time SULT1A1 as the essential factor.
We unambiguously proved that N-BIC sensitivity is depen-
dent on SULT1A1 protein. Furthermore, we showed how
N-BICs kill cells. We found that SULT1A1 converts the inac-
tive prodrugs, N-BICs, to strong electrophiles, to alkylate
many proteins for the killing of sufficient tumor cells. We
also found that there is little retention of N-BIC metabolites
in vivo. Therefore, N-BICs promise to be potential therapeu-
tic candidates for patients with tumors with high levels of
SULT1A1 protein expression.EXPERIMENTAL PROCEDURES
Chemical Synthesis
Detailed synthetic information for N-BIC 1, 2, and 3 can be found in the
Supplemental Information. Characterization of the novel compound N-BICChemistry & Biology 22, 1228–1233 is as follows: 1H NMR (400 MHz, methanol-d4) d ppm 7.67–7.78 (m,
4 H), 7.60 (s, 1 H), 7.29–7.42 (m, 4 H), 7.12 (ddd, J = 8.08, 7.07, 1.01 Hz,
1 H), 7.06 (ddd, J = 8.08, 7.07, 1.01 Hz, 1 H), 5.51 (s, 2 H), 4.42–4.55 (m,
2 H), 4.22 (dd, J = 7.58, 4.55 Hz, 1 H), 4.04 (dd, J = 8.08, 4.55 Hz, 1 H),
2.98–3.05 (m, 1 H), 2.74 (dd, J = 12.63, 5.05 Hz, 1 H), 2.57 (d, J =
13.14 Hz, 1 H), 2.26 (t, J = 7.33 Hz, 2 H), 1.60–1.71 (m, 3 H), 1.50–1.60
(m, 1 H), 1.33–1.41 (m, 2 H).
13C NMR (101 MHz, methanol-d4) d ppm 176.13, 166.19, 138.50, 138.05,
137.20, 134.35, 134.19, 129.51, 129.39, 129.18, 128.71, 127.65, 127.16,
126.67, 123.05, 120.52, 120.37, 116.66, 111.11, 63.27, 61.63, 57.19, 57.04,
50.98, 44.32, 41.15, 36.86, 29.69, 29.46, 27.02 (s, 1 C).
(m/z): [M-OH]+ calculated for C31H33N4O2S, 525.2324; found, 525.2313.
Cell Culture
Caov-3, HLE, HLF, and HUH1 were maintained in DMEM (Invitrogen,
#11995). H1299 and SNU475 were maintained in RPMI-1640 medium
(Invitrogen, #11875). C3A and Hep_G2 were cultured in EMEM (ATCC,
#30-2003). Saos-2, HT29, and HCT116 cells were cultured in McCoy’s 5A
medium (Invitrogen, #16600). All media were supplemented with 10% fetal
bovine serum.
Cell Viability Assay
Cells were seeded to 384-well plates at 20,000 cells for liver cell lines, 8,000
cells for Caov-3, and 4,000 cells for all other cell lines in 36 ml of medium
and treated with 4 ml of compounds on the second day. Cell viability was deter-
mined with CellTiter-Glo Luminescent Cell Viability Assay (Promega, #G7572)
after 72 hr of treatment.
Colony Formation Assay
HCT116 p53 Mut cells (1,000 cells in 3 ml of medium) were seeded onto six-
well plates and treated with indicated compounds. Medium and compound
were refreshed every other day. At day 13, cells were washed with PBS, fixed,
and stained in Crystal Violet staining solution for 30 min. After washing with
PBS, plates were dried and scanned.
SULT1A1 Knockdown with shRNA
shRNA lentiviral plasmids (shRNA1, 50-CCG GGA CAT GAA GGA GAA CCC
GAA ACT CGA GTT TCG GGT TCT CCT TCA TGT CTT TTT G; shRNA2,
50-CCG GAC GCA AAG GAT GTG GCA GTT TCT CGA GAA ACT GCC
ACA TCC TTT GCG TTT TTT G; shRNA3, 50-CCG GAG TTT CCT ACT
ACC ACT TCT ACT CGA GTA GAA GTG GTA GTA GGA AAC TTT TTT G)
and pLKO.1-puro Non-Target shRNA control plasmid DNA (SHC016) were
purchased from Sigma. Lentiviral particles were made by co-transfection
of viral packaging constructs VSVG and Delta 8.9 and shRNA lentiviral
plasmids into 293T cells, and collected at 48 and 72 hr. Lentiviral particles
(1 ml) were then added to the cells in 2 ml of Polybrene (8 mg/ml). 48 hr
after infection, 1 mg/ml puromycin was applied for selection of stable cell
lines.
Western Blotting
Cell pellet was lysed in 50 mM Tris-HCl (pH 7.4), with 150 mM NaCl, 1 mM
EDTA, and 1% Triton X-100, plus protease inhibitor cocktail (Roche,
#11836153001). The cell lysate was separated on Criterion Tris-HCl precast
Gels (Bio-Rad, #345-0033) and transferred to Nitrocellulose membranes.
The membranes were blocked with 10% fat-free milk in Tris-HCl
buffered saline plus 0.1% Tween 20 (TBST) for 1 hr. They were then incu-
bated with either goat anti-SULT1A1 antibody (R&D, #AF5546) at 1:250 dilu-
tion, mouse anti-p53 (Santa Cruz Biotechnology, #sc-126) at 1:1,000 dilu-
tion, rabbit anti-Nrf2 antibody (EP1808Y) (Abcam, #ab62352) at 1:500
dilution, or mouse anti-b-actin (Sigma, #A1978) at 1:20,000 dilution in
10% milk in TBST at 4C overnight. After three 10-min washes with TBST,
the membranes incubated with donkey antigoat immunoglobulin-horse-
radish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz, #sc-
2020) at 1:500 dilution for SULT1A1 or with goat antimouse HRP-conjugated
secondary antibody (Pierce, #31430) at 1:1,000 dilution for p53 and
1:40,000 dilution for b-actin, or with goat antirabbit HRP-conjugated sec-
ondary antibody (Pierce, #31460) at 1:1,000 dilution in 10% milk in TBST
for 1 hr at room temperature. After three washes with TBST, the membranes7, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1235
were incubated with ECL Western Blotting Substrate (Pierce, #32106) and
exposed to films.
Quantitative Real-Time PCR
Total RNA was prepared using RNeasy mini (Qiagen, #74104). cDNAs were
synthesized with a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, #4368813). qPCR was performed with SYBR Green PCR
Master Mix (Applied Biosystems, #4364346) and QuantiTect Primer Assay
for SULT1A1 (Qiagen, #QT01665489) and b-actin (Qiagen, #QT01680476).
SULT1A1 expression level was normalized to that of b-actin.
Biochemical SULT1A1 Assay
A colorimetric assay for SULT1A1 activity was adapted from Frame et al.
(2000). In brief, SULT1A1, PAPS, 2-Napthol, and test compound were com-
bined in 2-(N-morpholino)ethanesulfonic acid buffer and incubated for various
time periods. SULT1A1 uses PAPS to transfer a sulfate to the test substrate,
with PAPS as a by-product. p-Nitrophenyl sulfate in the system can be used
to regenerate PAPS from PAP. In doing so, p-nitrophenol is released, which
is UV active and can be quantified. Reaction linear range was determined by
taking absorbance readings at 405 nm (Envision plate reader, PerkinElmer)
over a time course up to 3 hr.
Scheme modified from Frame et al. (2000).
Detection of N-BIC-Binding Proteins
Cells were treated with N-BIC 3 or pretreated with test compounds for 3 hr and
then treated with N-BIC 3 for 16 hr. N-BIC-binding proteins were detected with
HRP-conjugated streptavidin (Pierce, #21130) by enhanced chemilumines-
cence or with Alexa Fluor 488 conjugated streptavidin (Invitrogen, #S11223)
by fluorescence microscopy.
Measurement of N-BIC 1 Level in Cells
N-BIC 1 from cell lysate was analyzed by using high-performance liquid chro-
matography (HPLC) separation coupled with mass spectrometric detection.
The detailed liquid chromatography-mass spectrometry (LC-MS) method is
given in the Supplemental Information.
In Vivo Efficacy Experiments
All procedures involving laboratory animals were approved by the Novartis
Institutes for Biomedical Research Institutional Animal Care and Use Com-
mittee, and were in accordance with federal, state, and local guidelines gov-
erning the use of laboratory animals in research. Female outbred athymic
nu/nu mice, age 7 weeks (Taconic Farms) were inoculated subcutaneously,
in the dorsal axillary region, with either 2 3 106 HT-29 or 2 3 106 HCT116
cells suspended in sterile media. Tumor volume was determined by caliper
measurements obtained in two dimensions and calculated as width2 3
length/2. Treatment was initiated when average tumor volume reached
100 mm3, after animal groups were randomized based on tumor volume.
Subsequent tumor volume and animal weight were measured every 3 or
4 days. N-BIC 1 was formulated in 10% ethanol, 10% Cremophore EL,
and 20% Solutol in PBS, and delivered via intraperitoneal route for all
experiments.
Pharmacokinetic Experiments
Detailed information on the LC-MS analysis of N-BIC 1 can be found in the
Supplemental Information.
Measurement of N-BIC 1 in Mouse Tumor or Plasma
Tumor tissue was diluted 3-fold (w/w) with PBS/acetonitrile (85:15) and
homogenized. A 25-ml aliquot of homogenized tumor or mouse plasma was
subjected to protein precipitation. The supernatant was analyzed by HPLC
separation coupled with mass spectrometric detection.1236 Chemistry & Biology 22, 1228–1237, September 17, 2015 ª201SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2015.06.025.
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